Polygenic Screening: What’s the use?

A theoretical framework predicts that using polygenic screening to select embryos against traits that depend on many genes has few benefits.
  1. Jason M Fletcher
  2. Yuchang Wu
  3. Qiongshi Lu  Is a corresponding author
  1. Department of Sociology, University of Wisconsin-Madison, United States
  2. La Follette School of Public Affairs, University of Wisconsin-Madison, United States
  3. Center for Demography of Health and Aging, University of Wisconsin-Madison, United States
  4. Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, United States

Using genetic tests to select ‘designer babies’ has been a subject of science fiction for generations, but it is now getting closer to becoming a reality. Like in many other areas of science, techniques are progressing much faster than ethical and policy discussions (Conley and Fletcher, 2017). Indeed, many parents already genetically screen embryos produced using in vitro fertilization (IVF) to avoid passing on genetic variants that are known to directly cause genetic disorders (Baruch et al., 2008).

However, the plummeting cost of genetic sequencing and the sophistication of the tools used to predict characteristics based on the genetics of an individual will soon make it possible to screen for ‘complex traits’ – this is, traits that depend on many genes. This type of analysis is called polygenic screening. In short, it assesses the probability of an embryo exhibiting a trait (such as a health condition) based on the collection of genetic variants it carries that are known to influence that trait. Polygenic screening could allow couples to produce several embryos through IVF, check how likely each one is to manifest one or several complex traits, and, based on that information, decide which embryo to implant. Unlike screening for conditions that depend on a single gene, however, polygenic screening cannot always guarantee that an embryo will manifest a condition. The traits that can be tested for using polygenic screening include many health outcomes, but also characteristics that are more controversial to target, such as the IQ of a future baby (Lázaro-Muñoz et al., 2021).

Now, in eLife, Todd Lencz (Zucker School of Medicine at Hofstra/Northwell and Northwell Health), Shai Carmi (Hebrew University of Jerusalem) and colleagues – including Daniel Backenroth (Hebrew University) as joint first author with Lencz – report on the usefulness of polygenic screening when testing for complex health traits, such as schizophrenia and Crohn’s disease (Lencz et al., 2021). Briefly, the utility of screening will depend on the predictive accuracy of the genetic tests performed and, more subtly, on the goal of the testing as well as the setting – that is, who specifically is being tested, and for what.

Lencz et al. largely take predictive accuracy as a given (but see Fletcher et al., 2021 for issues of accuracy), and employ a theoretical framework to ask deeper questions about the usefulness of several strategies that can be used when selecting embryos. First, Lencz et al. assume that a hypothetical couple produces several viable embryos via IVF. The probability of each of those embryos having a specific complex trait (for example, a given health condition) can be determined using polygenic screening. Based on these probabilities, the couple must then choose which embryo to implant. Starting from these assumptions, Lencz et al. compare the utility of different approaches to selection. Finally, Lencz et al. use genome data from schizophrenia and Crohn’s disease case-control studies to simulate virtual couples and their offspring and confirm their predictions.

Lencz et al. found that, in general, polygenic screening is not very useful when it targets complex health traits. This is because most selections occur between embryos with the same parents, which substantially limits both genetic and environmental variability. Thus, when selecting for specific characteristics, there is only a small number of possible outcomes, which reduces the usefulness of any selection regime. But, within this constraint, focusing on binary traits (for example, an embryo having or not having a disease) illuminates an important asymmetry in the utility of selection. Take, for example, the case of a couple having to select one of five embryos for implantation. The benefits of ruling out the one or two embryos with the highest risk scores, and then selecting from the remaining three or four embryos by chance are small. This is because although a couple is choosing at random between three embryos that do not have the highest risk of the disease, each of them could still be at a moderate risk of having the disease. Instead, a better strategy is to pick the embryo with the lowest risk score.

However, this result provides the first reason why parents, if they are well-informed, are unlikely to perform polygenic screening. Assuming that the negative attitudes most Americans have against enhancing traits through gene editing extend to genetic screening, parents are likely to want to screen embryos to avoid disease, but are probably against choosing the ‘best’ embryo (Scheufele et al., 2017).

Even if parents (counter to intuition) did want to choose the ‘best’ embryo, deciding which is the ‘best’ soon becomes an impossible task. Lencz et al. only consider the situation where parents are choosing between embryos more or less likely to exhibit one or two complex traits; but what happens when several traits, each dependent on many genes, are of interest? A decrease in the risk of one health condition, for example, could lead to an increase in the risk of another. Trading off risks between schizophrenia and Crohn’s disease would be difficult, but when other characteristics such as genetic risks for height, IQ, and eye color are thrown into the mix, the decision becomes impossible. This ‘paradox of choice’ is a second reason that parents will not choose polygenic screening if they are properly informed about it (Schwartz, 2004).

For both of these reasons, the analysis by Lencz et al. places critical focus on the lack of utility of genetic screening for complex traits, and the findings are an incredibly important contribution for science and for public and policy discussions. Nevertheless, a number of questions about the value of polygenic screening still remain. Lencz et al. answer the (constrained) question of which embryo to choose if you must choose one. Indeed, if there are five embryos with similar risks to pick from, Lencz et al. assume that parents will select one randomly. A related question is whether these parents should implant one of the five embryos they already have, or wait to use others. This may be answered using a method that predicts whether a couple are likely to produce a lower-risk embryo than the ones they already have, based on the parents’ genetic information (Chen et al., 2020).

An obvious next step will be to study actual couples (and not virtual couples as done by Lencz et al.) because couples in the real world are likely to be more genetically similar than couples chosen at random (Domingue et al., 2014; Conley et al., 2016). Like the selection question raised by Lencz et al., this use of polygenic screening opens a large set of ethical questions as well as questions about the utility of the approach that are not yet fully answered.

References

  1. Book
    1. Conley D
    2. Fletcher J
    (2017)
    The Genome Factor
    Princeton University Press.
  2. Book
    1. Schwartz B
    (2004)
    The Paradox of Choice: Why More Is Less
    New York: Ecco.

Article and author information

Author details

  1. Jason M Fletcher

    Jason M Fletcher is in the Department of Sociology, La Follette School of Public Affairs and Center for Demography of Health and Aging at the University of Wisconsin-Madison, Madison, United States

    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8843-0563
  2. Yuchang Wu

    Yuchang Wu is in the Center for Demography of Health and Aging and Department of Biostatistics and Medical Informatics at University of Wisconsin-Madison, Madison, United States

    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6985-3998
  3. Qiongshi Lu

    Qiongshi Lu is in the Center for Demography of Health and Aging and Department of Biostatistics and Medical Informatics at University of Wisconsin-Madison, Madison, United States

    For correspondence
    qlu@biostat.wisc.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4514-0969

Publication history

  1. Version of Record published:

Copyright

© 2021, Fletcher et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,984
    views
  • 87
    downloads
  • 1
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jason M Fletcher
  2. Yuchang Wu
  3. Qiongshi Lu
(2021)
Polygenic Screening: What’s the use?
eLife 10:e73193.
https://doi.org/10.7554/eLife.73193

Further reading

    1. Chromosomes and Gene Expression
    2. Genetics and Genomics
    Hasiba Asma, Ellen Tieke ... Marc S Halfon
    Tools and Resources

    Annotation of newly sequenced genomes frequently includes genes, but rarely covers important non-coding genomic features such as the cis-regulatory modules—e.g., enhancers and silencers—that regulate gene expression. Here, we begin to remedy this situation by developing a workflow for rapid initial annotation of insect regulatory sequences, and provide a searchable database resource with enhancer predictions for 33 genomes. Using our previously developed SCRMshaw computational enhancer prediction method, we predict over 2.8 million regulatory sequences along with the tissues where they are expected to be active, in a set of insect species ranging over 360 million years of evolution. Extensive analysis and validation of the data provides several lines of evidence suggesting that we achieve a high true-positive rate for enhancer prediction. One, we show that our predictions target specific loci, rather than random genomic locations. Two, we predict enhancers in orthologous loci across a diverged set of species to a significantly higher degree than random expectation would allow. Three, we demonstrate that our predictions are highly enriched for regions of accessible chromatin. Four, we achieve a validation rate in excess of 70% using in vivo reporter gene assays. As we continue to annotate both new tissues and new species, our regulatory annotation resource will provide a rich source of data for the research community and will have utility for both small-scale (single gene, single species) and large-scale (many genes, many species) studies of gene regulation. In particular, the ability to search for functionally related regulatory elements in orthologous loci should greatly facilitate studies of enhancer evolution even among distantly related species.

    1. Biochemistry and Chemical Biology
    2. Genetics and Genomics
    Ting Liu, Xing Shen ... Zhihong Xue
    Research Article

    The interplay between G4s and R-loops are emerging in regulating DNA repair, replication, and transcription. A comprehensive picture of native co-localized G4s and R-loops in living cells is currently lacking. Here, we describe the development of HepG4-seq and an optimized HBD-seq methods, which robustly capture native G4s and R-loops, respectively, in living cells. We successfully employed these methods to establish comprehensive maps of native co-localized G4s and R-loops in human HEK293 cells and mouse embryonic stem cells (mESCs). We discovered that co-localized G4s and R-loops are dynamically altered in a cell type-dependent manner and are largely localized at active promoters and enhancers of transcriptional active genes. We further demonstrated the helicase Dhx9 as a direct and major regulator that modulates the formation and resolution of co-localized G4s and R-loops. Depletion of Dhx9 impaired the self-renewal and differentiation capacities of mESCs by altering the transcription of co-localized G4s and R-loops -associated genes. Taken together, our work established that the endogenous co-localized G4s and R-loops are prevalently persisted in the regulatory regions of active genes and are involved in the transcriptional regulation of their linked genes, opening the door for exploring broader roles of co-localized G4s and R-loops in development and disease.